CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Gyre Therapeutics Inc - GYRE CFD

    16.0992
    31.05%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.1516
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026235 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026235%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004012 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004012%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 0.01
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Gyre Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 23.3492
    Open* 24.5992
    1-Year Change* 4388.09%
    Day's Range* 16.0992 - 24.5992
    52 wk Range 2.83-17.41
    Average Volume (10 days) 90.13K
    Average Volume (3 months) 769.23K
    Market Cap 32.23M
    P/E Ratio -100.00K
    Shares Outstanding 2.53M
    Revenue N/A
    EPS -20.60
    Dividend (Yield %) N/A
    Beta 1.29
    Next Earnings Date Mar 28, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 1, 2023 23.3492 1.1300 5.09% 22.2192 25.0292 21.6992
    Nov 30, 2023 23.3092 -2.5900 -10.00% 25.8992 25.8992 21.3292
    Nov 29, 2023 26.0892 0.3400 1.32% 25.7492 26.8992 24.0092
    Nov 28, 2023 24.0092 3.0000 14.28% 21.0092 26.2992 21.0092
    Nov 27, 2023 20.8192 1.3200 6.77% 19.4992 20.8992 17.5292
    Nov 24, 2023 19.0392 1.8300 10.63% 17.2092 19.8992 17.2092
    Nov 22, 2023 16.0992 2.8600 21.60% 13.2392 16.4092 13.2392
    Nov 21, 2023 12.4792 -1.7200 -12.11% 14.1992 14.1992 11.7992
    Nov 20, 2023 14.4992 -1.1000 -7.05% 15.5992 17.2992 14.2692
    Nov 17, 2023 14.4092 1.4100 10.85% 12.9992 14.4992 12.9992
    Nov 16, 2023 12.8192 0.2200 1.75% 12.5992 13.7192 12.5992
    Nov 15, 2023 12.1492 2.6500 27.90% 9.4992 12.6592 9.4992
    Nov 14, 2023 9.2892 0.2000 2.20% 9.0892 9.4792 8.9592
    Nov 13, 2023 8.8592 0.0500 0.57% 8.8092 9.0992 8.6992
    Nov 10, 2023 8.6992 -0.4200 -4.61% 9.1192 9.1992 8.2992
    Nov 9, 2023 8.6692 -0.8400 -8.83% 9.5092 10.2492 8.4992
    Nov 8, 2023 9.1992 1.0100 12.33% 8.1892 9.2492 8.0992
    Nov 7, 2023 8.0492 0.6900 9.38% 7.3592 8.0992 7.3592
    Nov 6, 2023 7.1592 0.4100 6.07% 6.7492 7.3292 6.7492
    Nov 3, 2023 6.4392 0.0700 1.10% 6.3692 6.5192 6.3192

    Gyre Therapeutics Inc Events

    Time (UTC) Country Event
    Thursday, March 28, 2024

    Time (UTC)

    12:30

    Country

    US

    Event

    Q4 2023 Catalyst Biosciences Inc Earnings Release
    Q4 2023 Catalyst Biosciences Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0.794 7.338 20.948 0 0.006
    Revenue 0.794 7.338 20.948 0 0.006
    Total Operating Expense 9.225 95.232 78.318 57.277 33.828
    Selling/General/Admin. Expenses, Total 16.966 18.963 16.18 13.418 12.354
    Research & Development 12.437 68.889 52.175 43.859 21.474
    Operating Income -8.431 -87.894 -57.37 -57.277 -33.822
    Interest Income (Expense), Net Non-Operating 0.537 0.039 0.561 2.145 2.233
    Gain (Loss) on Sale of Assets 0 -0.116
    Net Income Before Taxes -7.894 -87.933 -56.241 -55.178 -30.055
    Net Income After Taxes -8.242 -87.933 -56.241 -55.178 -30.055
    Net Income Before Extra. Items -8.242 -87.933 -56.241 -55.178 -30.055
    Net Income -8.242 -87.933 -56.241 -55.178 -30.055
    Income Available to Common Excl. Extra. Items -8.242 -87.933 -56.241 -55.178 -30.055
    Income Available to Common Incl. Extra. Items -8.242 -87.933 -56.241 -55.178 -30.055
    Diluted Net Income -8.242 -87.933 -56.241 -55.178 -30.055
    Diluted Weighted Average Shares 31.5457 30.641 19.1793 12.0045 11.2139
    Diluted EPS Excluding Extraordinary Items -0.26127 -2.86978 -2.93238 -4.59645 -2.68016
    Diluted Normalized EPS -0.30083 -2.86978 -2.89067 -4.59645 -2.66982
    Total Extraordinary Items
    Total Adjustments to Net Income 0
    Other, Net 0 -0.078 0.568 -0.046 1.65
    Cost of Revenue, Total 0.798 7.38 9.163
    Gross Profit -0.004 -0.042 11.785
    Unusual Expense (Income) -20.976 0.8
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total revenue 0 0 0 0 0
    Revenue 0 0 0 0 0
    Cost of Revenue, Total 0 0 0 0 0
    Gross Profit 0 0 0 0 0
    Total Operating Expense 1.623 2.543 -0.178 40.274 5.166
    Selling/General/Admin. Expenses, Total 2.408 2.225 3.97 4.165 4.363
    Research & Development 0.415 0.318 0.588 0.66 0.803
    Operating Income -1.623 -2.543 0.178 -40.274 -5.166
    Interest Income (Expense), Net Non-Operating 0.047 0.073 0.096 0.167 0.283
    Other, Net 0.001 -0.001
    Net Income Before Taxes -1.576 -2.47 0.274 -40.106 -4.884
    Net Income After Taxes -1.576 -2.472 0.26 -40.454 -4.884
    Net Income Before Extra. Items -1.576 -2.472 0.26 -40.454 -4.884
    Net Income -1.576 -2.472 0.26 -40.454 -4.884
    Income Available to Common Excl. Extra. Items -1.576 -2.472 0.26 -40.454 -4.884
    Income Available to Common Incl. Extra. Items -1.576 -2.472 0.26 -40.454 -4.884
    Diluted Net Income -1.576 -2.472 0.26 -40.454 -4.884
    Diluted Weighted Average Shares 37.9768 37.8001 37.9843 31.7649 31.4845
    Diluted EPS Excluding Extraordinary Items -0.0415 -0.0654 0.00684 -1.27354 -0.15512
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.0415 -0.0654 -0.0742 -0.15821 -0.15512
    Unusual Expense (Income) 0 0 -4.736 35.449 0
    Other Operating Expenses, Total -1.2
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 28.206 51.476 89.51 96.066 123.991
    Cash and Short Term Investments 21.666 46.851 79.354 76.865 120.127
    Cash & Equivalents 21.666 44.347 30.36 15.369 31.213
    Short Term Investments 0 2.504 48.994 61.496 88.914
    Total Receivables, Net 5 1.818 3.313 15
    Accounts Receivable - Trade, Net 5 1.818 3.313 15
    Prepaid Expenses 1.54 2.807 6.843 4.201 3.814
    Other Current Assets, Total 0 0.05
    Total Assets 28.444 55.662 94.846 98.554 124.92
    Property/Plant/Equipment, Total - Net 0.07 3.714 2.265 2.231 0.386
    Property/Plant/Equipment, Total - Gross 0.671
    Accumulated Depreciation, Total -0.285
    Other Long Term Assets, Total 0.168 0.472 0.528 0.257 0.543
    Total Current Liabilities 16.824 14.165 17.796 28.899 4.801
    Accounts Payable 0.194 6.419 5.931 4.279 1.248
    Accrued Expenses 4.072 7.516 9.882 9.62 3.538
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 12.558 0.23 1.983 15 0.015
    Total Liabilities 16.824 14.573 18.777 30.218 4.975
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 0 0.408 0.981 1.319 0.174
    Total Equity 11.62 41.089 76.069 68.336 119.945
    Common Stock 0.037 0.031 0.022 0.012 0.012
    Additional Paid-In Capital 389.21 443.752 390.803 326.81 323.279
    Retained Earnings (Accumulated Deficit) -410.936 -402.694 -314.761 -258.52 -203.342
    Other Equity, Total 0 0.005 0.034 -0.004
    Total Liabilities & Shareholders’ Equity 28.444 55.662 94.846 98.554 124.92
    Total Common Shares Outstanding 2.51723 2.09409 1.47326 0.80276 0.79701
    Redeemable Preferred Stock 33.309 0
    Total Preferred Shares Outstanding 0 0
    Long Term Investments 0 2.543
    Preferred Stock - Non Redeemable, Net 0
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 5.132 7.62 14.014 28.206 30.246
    Cash and Short Term Investments 2.228 6.923 8.099 21.666 23.09
    Cash & Equivalents 2.228 6.923 8.099 21.666 23.09
    Short Term Investments 0 0
    Total Receivables, Net 1.2 0 5 5 5
    Accounts Receivable - Trade, Net 0 0 5 5 5
    Prepaid Expenses 1.704 0.697 0.915 1.54 2.156
    Total Assets 9.964 12.394 18.75 28.444 31.019
    Property/Plant/Equipment, Total - Net 0 0 0.018 0.07 0.605
    Other Long Term Assets, Total 0.168 0.168 0.168 0.168 0.168
    Total Current Liabilities 1.783 2.793 6.844 16.824 1.644
    Accounts Payable 0.158 0.005 0.016 0.194 0.041
    Accrued Expenses 1.625 2.788 1.828 4.072 1.603
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0 0 5 12.558 0
    Total Liabilities 6.447 7.399 11.394 16.824 1.644
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 4.664 4.606 4.55 0 0
    Total Equity 3.517 4.995 7.356 11.62 29.375
    Common Stock 0.037 0.037 0.037 0.037 0.031
    Additional Paid-In Capital 384.895 384.797 384.686 389.21 399.826
    Retained Earnings (Accumulated Deficit) -414.724 -413.148 -410.676 -410.936 -370.482
    Other Equity, Total
    Total Liabilities & Shareholders’ Equity 9.964 12.394 18.75 28.444 31.019
    Total Common Shares Outstanding 2.532 2.53179 2.51745 2.51723 2.09944
    Long Term Investments
    Preferred Stock - Non Redeemable, Net 0
    Redeemable Preferred Stock 33.309 33.309 33.309 33.309
    Note Receivable - Long Term 4.664 4.606 4.55
    Total Preferred Shares Outstanding 0.01234 0.01234
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -8.242 -87.933 -56.241 -55.178 -30.055
    Cash From Operating Activities -33.096 -83.755 -55.048 -43.613 -28.553
    Cash From Operating Activities 0.23 0.29 0.138 0.146 0.149
    Non-Cash Items -20.139 3.405 3.627 3.204 2.722
    Changes in Working Capital -4.945 0.483 -2.572 8.215 -1.369
    Cash From Investing Activities 55.426 48.189 9.663 27.392 -71.321
    Capital Expenditures 0 -0.839 -0.267 -0.064 -0.376
    Other Investing Cash Flow Items, Total 55.426 49.028 9.93 27.456 -70.945
    Cash From Financing Activities -45.011 49.553 60.376 0.327 111.332
    Issuance (Retirement) of Stock, Net 0.02 49.553 60.376 0.327 116.414
    Issuance (Retirement) of Debt, Net 0 -5.082
    Net Change in Cash -22.681 13.987 14.991 -15.894 11.458
    Total Cash Dividends Paid -45.031
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line 0.26 -8.242 32.212 37.096 -14.536
    Cash From Operating Activities -6.216 -33.096 -31.621 -24.344 -12.05
    Cash From Operating Activities 0.003 0.23 0.22 0.18 0.113
    Non-Cash Items -4.526 -20.139 -55.85 -56.184 0.715
    Changes in Working Capital -1.953 -4.945 -8.203 -5.436 1.658
    Cash From Investing Activities 0.411 55.426 55.375 55.375 2.504
    Other Investing Cash Flow Items, Total 0.411 55.426 55.375 55.375 2.504
    Cash From Financing Activities -7.762 -45.011 -45.011 0.016 0.016
    Issuance (Retirement) of Stock, Net 0.002 0.02 0.02 0.016 0.016
    Net Change in Cash -13.567 -22.681 -21.257 31.047 -9.53
    Capital Expenditures 0 0 0
    Total Cash Dividends Paid -7.764 -45.031 -45.031

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Catalyst Biosciences, Inc. Company profile

    About Catalyst Biosciences Inc

    Catalyst Biosciences, Inc., formerly Targacept, Inc. is a research and clinical development biopharmaceutical company. The Company is focused on medical needs in disorders of the complement and coagulation systems. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously (SQ) administered engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders in patients with Hemophilia A or B with inhibitors. Its clinical trial of MarzAA in Factor VII Deficiency, Glanzmann Thrombasthenia, and Hemophilia A with inhibitor patients on prophylaxis Hemlibra for treatment of episodic bleeding (MAA-202). The Company pipeline also includes dalcinonacog alfa (DalcA), a subcutaneously (SQ) Factor IX (FIX) to prevent bleeding episodes for Hemophilia B patients. Its discovery stage Factor IX gene therapy construct, CB 2679d-GT for Hemophilia B.

    Financial summary

    BRIEF: For the nine months ended 30 September 2021, Catalyst Biosciences Inc revenues decreased 74% to $4.9M. Net loss increased 81% to $67.6M. Revenues reflect License decrease from $15.1M to $0K. Higher net loss reflects Research and development increase of 3% to $38.3M (expense), General and administrative - Balancing v increase of 9% to $11.3M (expense), Miscellaneous income (expense) decrease of 99% to $8K (income).

    Equity composition

    Common Stock $.001 Par, 04/11, 100M auth., 29,021,460 issd., Insiders control approx. 0.08%. IPO: 4/06 5,000,000 shs. @ $9per share by Deutsche Bank Securities. 8/15, 1-for-7 reverse stock split.

    Industry: Biotechnology & Medical Research (NEC)

    12770 High Bluff Drive, Suite 150
    SAN DIEGO
    CALIFORNIA 92130
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    Oil - Crude

    73.37 Price
    -1.470% 1D Chg, %
    Long position overnight fee -0.0200%
    Short position overnight fee -0.0019%
    Overnight fee time 22:00 (UTC)
    Spread 0.040

    BTC/USD

    41,800.65 Price
    +5.080% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Gold

    2,034.27 Price
    -1.820% 1D Chg, %
    Long position overnight fee -0.0200%
    Short position overnight fee 0.0118%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    XRP/USD

    0.62 Price
    -0.680% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading